| Identification | Back Directory | [Name]
6-[(3-aMinophenyl)Methyl]-4,6-dihydro-4-Methyl-2-(Methylsulfinyl)-5H-Thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one | [CAS]
1221186-53-3 | [Synonyms]
ML265
TEPP-46
CS-2036
ML 265;ML265
ML-265 TEPP-46
ML-265(TEPP-46)
TEPP 46 - ML 265
4,5]pyrrolo[2,3-d]pyridazin-5-one
]dodeca-1(8),2(6),4,11-tetraen-9-one
TEPP-46(ML265,CID-44246499,NCGC00186528)
6-[(3-aMinophenyl)Methyl]-4,6-dihydro-4-Methyl-2-(Methylsulfinyl)-5H-Thieno[2',3'
10-[(3-aminophenyl)methyl]-7-methyl-4-methylsulfinyl-3-thia-7,10,11-triazatricyclo[6.4.0.0<
6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5]pyrrolo[
2-methylsulfinyl-4-methyl-6-[(3-aminophenyl)methyl]-4H-thieno[3,2-b]pyrrole[3,2-d]pyridazinone
7-(3-aminobenzyl)-4-methyl-2-(methylsulfinyl)-4,7-dihydro-8H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-8-one
6-[(3-aMinophenyl)Methyl]-4,6-dihydro-4-Methyl-2-(Methylsulfinyl)-5H-Thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-on
6-[(3-aMinophenyl)Methyl]-4,6-dihydro-4-Methyl-2-(Methylsulfinyl)-5H-Thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
5H-Thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-
Name: 6-[(3-aMinophenyl)Methyl]-4,6-dihydro-4-Methyl-2-(Methylsulfinyl)-5H-Thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one | [Molecular Formula]
C17H16N4O2S2 | [MDL Number]
MFCD23160747 | [MOL File]
1221186-53-3.mol | [Molecular Weight]
372.46 |
| Chemical Properties | Back Directory | [Boiling point ]
711.6±70.0 °C(Predicted) | [density ]
1.58±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥37.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
A crystalline solid | [pka]
4.33±0.10(Predicted) | [color ]
White to light yellow | [InChI]
InChI=1S/C17H16N4O2S2/c1-20-13-7-14(25(2)23)24-16(13)12-8-19-21(17(22)15(12)20)9-10-4-3-5-11(18)6-10/h3-8H,9,18H2,1-2H3 | [InChIKey]
ZWKJWVSEDISQIS-UHFFFAOYSA-N | [SMILES]
C1(=O)N(CC2=CC=CC(N)=C2)N=CC2C3SC(S(C)=O)=CC=3N(C)C1=2 |
| Hazard Information | Back Directory | [Description]
Pyruvate kinase catalyzes the final step in glycolysis, the formation of pyruvate and ATP from phosphoenolpyruvate and ADP. The expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in the metabolic reprogramming of tumor cells, which require high amounts of glucose for proliferation. PKM2 is allosterically regulated by the upstream glycolytic intermediate, fructose-1,6-bisphosphate (FBP), which controls glycolysis in a feed forward mechanism.1 Whereas cancer cells exist in highly phosphorylated states, the binding of certain peptide motifs with phosphorylated tyrosines can inhibit PKM2 activity by causing the release of FBP from the allosteric site.1 ML-265 activates tumor-specific PKM2 (EC50 = 92 nM) by binding to the dimer-dimer interface between two subunits of PKM2 and inducing tetramerization, which is the most active form of the enzyme.2 It demonstrates >100-fold selectivity for PKM2 over the related PKM1, PKR, and PKL isoforms.2 At 50 mg/kg, ML-265 has been shown to reduce tumor size, weight, and occurrence in mice bearing H1299 cell xenografts in a model of human non-small cell lung carcinoma.2 | [Uses]
6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one is a pyruvate kinase M2 (PKM2) activator. It regulates lipid homeostasis in cancer cells and reverses aggressive cancer phenotypes. | [Definition]
ChEBI: 6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone is an organosulfur heterocyclic compound, an organonitrogen heterocyclic compound and an organic heterobicyclic compound. | [in vivo]
TEPP-46 exhibits good oral bioavailability with relatively low clearance, long half-life, and good volume of distribution-parameters that predict for drug exposure in tumor tissues. TEPP-46 at 150 mg/kg readily achieves maximal PKM2 activation measured in A549 xenograft tumors[1]. | [storage]
Store at -20°C | [References]
[1]. anastasiou d, yu y, israelsen wj, et al. pyruvate kinase m2 activators promote tetramer formation and suppress tumorigenesis. nat chem biol. 2012 oct;8(10):839-47.
[2]. walsh mj, brimacombe kr, anastasiou d, et al. ml265: a potent pkm2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. probe reports from the nih molecular libraries program [internet]. |
|
|